Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | CNR2 | P34972 | 6/20 | 0.33 |
| ▸ | CNR1 | P21554 | 5/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MERTK | Q12866 | 1/20 | 0.31 |
| ▸ | ICMT | O60725 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22624105 | 0.84 | KCNH2 (0.39) | KCNH2CNR2CNR1TLR8 | |
| SCHEMBL26326025 | 0.81 | KCNH2 (0.41) | KCNH2CNR2CNR1MEN1KMT2A | |
| SCHEMBL22375312 | 0.81 | KCNH2 (0.41) | KCNH2CNR2CNR1MEN1KMT2A | |
| SCHEMBL21731344 | 0.79 | MCHR1 (0.41) | KCNH2CNR2CNR1TLR8 | |
| SCHEMBL21731356 | 0.79 | MCHR1 (0.41) | KCNH2CNR2CNR1TLR8 | |
| SCHEMBL23745402 | 0.77 | KCNH2 (0.38) | KCNH2CNR2CNR1 | |
| SCHEMBL22375286 | 0.75 | KCNH2 (0.39) | KCNH2CNR2CNR1MEN1KMT2A | |
| SCHEMBL21191655 | 0.74 | LMNA (0.41) | SMN1; SMN2TLR8 | |
| SCHEMBL18745361 | 0.74 | LMNA (0.41) | SMN1; SMN2TLR8 | |
| SCHEMBL21478368 | 0.73 | FAAH (0.39) | KCNH2CNR2CNR1SMN1; SMN2TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308639-B2 | Phosphatidylinositol 3-kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2019-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308639-B2 | Phosphatidylinositol 3-kinase inhibitors | PIK3CA, AKT3, AKT2 | KCNH2 2850/4885CNR2 3870/4885CNR1 3626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.